Document Detail


Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI).
MedLine Citation:
PMID:  2868337     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
In an unblinded trial of intravenous streptokinase (SK) in early acute myocardial infarction, 11 806 patients in one hundred and seventy-six coronary care units were enrolled over 17 months. Patients admitted within 12 h after the onset of symptoms and with no contraindications to SK were randomised to receive SK in addition to usual treatment and complete data were obtained in 11 712. At 21 days overall hospital mortality was 10.7% in SK recipients versus 13% in controls, an 18% reduction (p = 0.0002, relative risk 0.81). The extent of the beneficial effect appears to be a function of time from onset of pain to SK infusion (relative risks 0.74, 0.80, 0.87, and 1.19 for the 0-3, 3-6, 6-9, and 9-12 h subgroups). SK seems to be a safe drug for routine administration in acute myocardial infarction.
Authors:
-
Related Documents :
21126977 - Marked variability in susceptibility to ventricular fibrillation in an experimental com...
3416327 - Early prediction of left ventricular function in streptokinase-treated acute myocardial...
2868337 - Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. gru...
2857087 - Prostacyclin infusion in patients with acute myocardial infarction.
9583227 - Identification of stroke prone patients by panoramic radiography.
9428617 - Catecholamine-induced cardiac hypertrophy: significance of proto-oncogene expression.
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Lancet     Volume:  1     ISSN:  0140-6736     ISO Abbreviation:  Lancet     Publication Date:  1986 Feb 
Date Detail:
Created Date:  1986-03-20     Completed Date:  1986-03-20     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  2985213R     Medline TA:  Lancet     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  397-402     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Cardiovascular Agents / therapeutic use
Clinical Trials as Topic
Female
Follow-Up Studies
Humans
Infusions, Parenteral
Male
Myocardial Infarction / drug therapy*,  mortality
Prospective Studies
Random Allocation
Streptokinase / administration & dosage,  therapeutic use*
Time Factors
Chemical
Reg. No./Substance:
0/Cardiovascular Agents; EC 3.4.-/Streptokinase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The future of general practice in Newcastle upon Tyne.
Next Document:  Small upper airway in near-miss sudden infant death syndrome infants and their families.